1260530-25-3

Basic information

• Product Name: GSK-525768A
• Synonyms: GSK 525768A;GSK525768A;GSK-525768A;(4R)-6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide;GSK-525768
• CAS NO: 1260530-25-3
• Molecular Formula: C22H22ClN5O2
• Molecular Weight: 423.89538
• Mol File: 1260530-25-3.mol
• Article Data: 1

Chemical Properties

• Melting Point: 140-145℃
• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• Solubility: Soluble in DMSO
• PKA: 15.71±0.46(Predicted)
• CAS DataBase Reference: GSK-525768A(CAS DataBase Reference)
• NIST Chemistry Reference: GSK-525768A(1260530-25-3)
• EPA Substance Registry System: GSK-525768A(1260530-25-3)

Safety Data

• Hazardous Substances Data: 1260530-25-3(Hazardous Substances Data)

Usage

General Description

GSK-525768A is a potent and selective inhibitor of the bromodomain and extra-terminal (BET) family of proteins, which play a key role in regulating gene expression. It has been shown to inhibit the binding of BET proteins to acetylated histones, thus disrupting the formation of transcriptional complexes and leading to suppression of gene transcription. GSK-525768A has demonstrated potential therapeutic effects in preclinical studies, particularly in the treatment of cancers and inflammatory diseases. Its mechanism of action and selectivity make it a promising candidate for further development as a therapeutic agent.

Relevant articles and documents

BENZODIAZEPINE BROMODOMAIN INHIBITOR

Benzodiazepine compounds of formula (I), and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.